Founded Year



Series A | Alive

Total Raised


Last Raised

$5.24M | 5 yrs ago

About Empatica

Empatica is a full-stack company that designs and develops AI systems to monitor human health through wearable sensors. The company provides a platform for the forecasting, monitoring, and treatment of medical conditions.

Empatica Headquarter Location

45 Bromfield St. Suite #901

Boston, Massachusetts, 02108,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Empatica's Products & Differentiation

See Empatica's products and how their products differentiate from alternatives and competitors

  • EmbracePlus Research Platform

    A platform with a medical-grade smartwatch and dedicated software, for clinical researchers to achieve cloud-based remote health monitoring and data collection at scale. Empatica's award-winning EmbracePlus smartwatch is CE-marked for its ability to collect quality physiological data from the wrist. The data is streamed to a participant phone via Bluetooth, and from there, using Empatica's Care App, it is streamed to the cloud for immediate download or visualization through an online dashboard. Empatica's cloud infrastructure enables data to be streamed from thousands of devices simultaneously.

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

Research containing Empatica

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Empatica in 1 CB Insights research brief, most recently on May 26, 2021.

Expert Collections containing Empatica

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Empatica is included in 9 Expert Collections, including Wearable Computing.


Wearable Computing

387 items

Wearable computing is broadly defined as companies developing devices worn or placed on the body that are equipped with technology, which can range from wearable medical devices to AR/VR headsets to GPS pet collars.


Artificial Intelligence

8,717 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.


Medical Devices

11,368 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health Monitoring & Diagnostics

3,694 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance


Smart Home & Consumer Electronics

1,086 items

This Collection includes companies developing smart home devices, wearables, home electronics, and other consumer electronics.


Digital Health

12,800 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

Empatica Patents

Empatica has filed 4 patents.

The 3 most popular patent topics include:

  • Cephalopod zootomy
  • Cuttlefish
  • Graphical projections
patents chart

Application Date

Grant Date


Related Topics




Graphical projections, Technical drawing, Light machine guns, Cephalopod zootomy, Cuttlefish


Application Date


Grant Date



Related Topics

Graphical projections, Technical drawing, Light machine guns, Cephalopod zootomy, Cuttlefish



Latest Empatica News

Beckley Psytech Announces Partnership With Empatica in Latest Step of Digital Strategy, Designed to Deliver Personalised Patient Care

May 19, 2022

Partnership will capture behavioural and physiological signals and predictive biomarkers in Beckley Psytech’s upcoming Phase 2 clinical trials New digital strategy aims to improve patient outcomes and safety by integrating advanced digital tools into the psychedelic treatment journey Download EmbracePlus is a medical-grade wearable that enables the passive, remote monitoring of physiological and behavioural signals. Photo credit: Empatica EmbracePlus is a medical-grade wearable that enables the passive, remote monitoring of physiological and behavioural signals. Photo credit: Empatica May 19, 2022 02:00 AM Eastern Daylight Time OXFORD, England--( BUSINESS WIRE )--Beckley Psytech Limited, a private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, and Empatica, Inc., a medical wearables and digital biomarker company offering continuous, passive, and unobtrusive monitoring for patients with neurological conditions, today announced that the companies have entered into a partnership to support the collection and analysis of behavioural and physiological data in Beckley Psytech’s future clinical trials. This partnership will utilise Empatica’s medical-grade EmbracePlus wearable and software, to identify and measure passive behavioural and physiological signals in the upcoming Phase 2 studies evaluating the use of 5-MeO-DMT in combination with psychotherapy in the treatment of treatment resistant depression (TRD). The strategic partnership with Empatica is the latest step in Beckley Psytech’s digital strategy to develop personalised treatment programmes for patients in need. The digital enhancement of the psychedelic treatment pathway aims to support patients before, during, and after treatment through the application of novel, predictive biomarkers which will potentially identify early signals of patient response and relapse. Beckley Psytech aims to establish a complete, end-to-end personalised psychedelic treatment programme, combining advanced digital phenotyping capabilities, such as those developed by Empatica, with psychedelic-assisted psychotherapy. This will allow clinicians to provide patients with continuous access to personalised therapy support beyond their treatment, delivering potentially improved outcomes and safety for patients and healthcare systems. Cosmo Feilding Mellen, CEO of Beckley Psytech, said: “As we look to enhance the safety and effectiveness of our psychedelic treatments with patient-centric digital tools, this partnership with Empatica accelerates our strategy of creating an integrated treatment model to ensure patients are fully supported through the treatment journey. We are thrilled to be working with Empatica, a pioneering digital health company, through our upcoming clinical trials and look forward to further evolving our understanding of how digital tools can support and potentially improve outcomes for patients with neurological and psychiatric conditions.” Matteo Lai, CEO of Empatica, commented: “We couldn’t be more excited to collaborate with Beckley Psytech on this important project, especially since over the past two years, we have witnessed how critical mental health and depression have become globally. The potential of psychedelic treatments in the field can help millions of patients, and Empatica is honored to contribute its technology in one of the world’s first trials with psychedelics and digital tools, to advance these novel therapies with targeted help and better engagement.” About 5-MeO-DMT 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a psychoactive compound which binds to a variety of receptors within the brain pertaining to serotonin. A psychedelic substance which occurs naturally in a number of plant species, as well as in the Sonoran Desert toad, studies have indicated that 5-MeO-DMT is associated with improvements in mood, anxiety, reduced stress, increased life satisfaction and mindfulness. 5-MeO-DMT has been reported to produce mystical experiences with comparative intensity as seen with high doses of psilocybin but has a significantly shorter duration of effect. Beckley Psytech is developing proprietary synthetic intranasal formulations of 5-MeO-DMT (BPL-002 and BPL-003) and plans to evaluate their potential therapeutic effects in patients suffering from Treatment Resistant Depression, as well as other Mood and Use Disorders indications. Beckley Psytech is a clinical stage privately held company dedicated to helping patients suffering from neurological and psychiatric disorders by developing a broad pipeline of psychedelic compounds in rare and more common diseases. Our vision is for clinically validated psychedelic medicines to be integrated into modern medical practice in order to help patients with high unmet medical need around the world suffering with treatment resistant depression, and other profoundly debilitating neurological conditions. Beckley Psytech was founded in 2019 leveraging some of the expertise developed over more than 20 years by the Beckley Foundation, an independent non-profit and world leader in psychedelic medicine research, and is based out of Oxford, United Kingdom. Empatica Inc is a pioneer in continuous, unobtrusive, and remote health monitoring driven by AI. Empatica's platform combines accurate digital biomarkers, software and wearables to monitor multiple conditions. Empatica's products are used by thousands of institutional partners for research purposes, in trials and studies examining Stress, Sleep, Epilepsy, Migraine, Depression, Addiction, and other conditions. Contacts

Empatica Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Empatica Rank

  • When was Empatica founded?

    Empatica was founded in 2011.

  • Where is Empatica's headquarters?

    Empatica's headquarters is located at 45 Bromfield St., Boston.

  • What is Empatica's latest funding round?

    Empatica's latest funding round is Series A.

  • How much did Empatica raise?

    Empatica raised a total of $5.24M.

  • Who are Empatica's competitors?

    Competitors of Empatica include Biofourmis and 8 more.

  • What products does Empatica offer?

    Empatica's products include EmbracePlus Research Platform and 2 more.

  • Who are Empatica's customers?

    Customers of Empatica include Pear Therapeutics.

You May Also Like

NYX Technologies

NYX Technologies has developed a wearable device to help users improve their sleep and reduce stress. The device is a wearable brain-tech headset that stimulates and monitors the user's brain activity.

Whoop Logo

Whoop makes a fitness tracker that is popular with professional athletes. Whoop describes itself as a personal digital fitness and health coach and monitors sleep, strain and recovery.

Withings Logo

Withings creates smart products and apps to help people across the world take care of their health and well-being. By extending the capabilities of an object through network resources, Withings provides access to computing and storage facility at no extra cost, turning objects into smart connected devices.

MyFitnessPal Logo

MyFitnessPal offers a free platform for achieving and maintaining health goals with a database of more than 3 million foods and hundreds of exercises, top fitness technology partners and community insights. To date, the company has been used by more than 40 million people.

Dozee Logo

Turtle Shell Technologies develops Dozee, a contactless health monitor that silently tracks users' heart, respiration, and sleep patterns while they sleep. The smart algorithms also enable early detection of any health deterioration helping users to stay on top of their health.

PhysIQ Logo

PhysIQ enables proactive care delivery models through its proprietary, FDA-cleared Personalized Physiology Analytics technology. PhysIQ offers a platform designed to process multiple vital signs from biosensors to create a personalized dynamic baseline for each individual. By mapping vital sign relationships, physIQ's analytics detect subtle deviations that may be a precursor to disease exacerbation or change in health.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.